Cargando…
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis
BACKGROUND: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. METHODS: Patient-level data were pooled from two randomized cli...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380564/ https://www.ncbi.nlm.nih.gov/pubmed/22081557 http://dx.doi.org/10.1002/dmrr.1305 |
_version_ | 1782236314563772416 |
---|---|
author | Chaudhuri, Ajay Rosenstock, Julio DiGenio, Andres Meneghini, Luigi Hollander, Priscilla McGill, Janet B Dandona, Paresh Ilgenfritz, John Riddle, Matthew |
author_facet | Chaudhuri, Ajay Rosenstock, Julio DiGenio, Andres Meneghini, Luigi Hollander, Priscilla McGill, Janet B Dandona, Paresh Ilgenfritz, John Riddle, Matthew |
author_sort | Chaudhuri, Ajay |
collection | PubMed |
description | BACKGROUND: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. METHODS: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18 years, diagnosed with type 2 diabetes for at least 6 months, on metformin and/or sulphonylurea, and with A(1C) ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. RESULTS: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. CONCLUSION: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs. Copyright © 2011 John Wiley & Sons, Ltd. |
format | Online Article Text |
id | pubmed-3380564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33805642012-06-26 Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis Chaudhuri, Ajay Rosenstock, Julio DiGenio, Andres Meneghini, Luigi Hollander, Priscilla McGill, Janet B Dandona, Paresh Ilgenfritz, John Riddle, Matthew Diabetes Metab Res Rev Research Articles BACKGROUND: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. METHODS: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18 years, diagnosed with type 2 diabetes for at least 6 months, on metformin and/or sulphonylurea, and with A(1C) ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. RESULTS: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p < 0.0003), 7.5% greater reduction in non-HDL-C (p < 0.0001), and 7.8% greater reduction in total cholesterol (p < 0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p < 0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. CONCLUSION: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs. Copyright © 2011 John Wiley & Sons, Ltd. John Wiley & Sons, Ltd 2012-03 /pmc/articles/PMC3380564/ /pubmed/22081557 http://dx.doi.org/10.1002/dmrr.1305 Text en Copyright © 2011 John Wiley & Sons, Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Research Articles Chaudhuri, Ajay Rosenstock, Julio DiGenio, Andres Meneghini, Luigi Hollander, Priscilla McGill, Janet B Dandona, Paresh Ilgenfritz, John Riddle, Matthew Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title_full | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title_fullStr | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title_full_unstemmed | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title_short | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
title_sort | comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380564/ https://www.ncbi.nlm.nih.gov/pubmed/22081557 http://dx.doi.org/10.1002/dmrr.1305 |
work_keys_str_mv | AT chaudhuriajay comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT rosenstockjulio comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT digenioandres comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT meneghiniluigi comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT hollanderpriscilla comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT mcgilljanetb comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT dandonaparesh comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT ilgenfritzjohn comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis AT riddlematthew comparingtheeffectsofinsulinglargineandthiazolidinedionesonplasmalipidsintype2diabetesapatientlevelpooledanalysis |